Johnson & Johnson (NYSE:JNJ)‘s stock had its “outperform” rating reaffirmed by research analysts at Wells Fargo & Company in a note issued to investors on Wednesday, October 18th, The Fly reports. They presently have a $155.00 price objective on the stock, up from their prior price objective of $149.00. Wells Fargo & Company’s price target points to a potential upside of 9.30% from the company’s current price.
JNJ has been the subject of a number of other research reports. Credit Suisse Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Friday, August 4th. Piper Jaffray Companies reiterated a “hold” rating and issued a $120.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 4th. Vetr cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target for the company. in a research note on Monday, September 18th. Alembic Global Advisors cut shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. Finally, Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research note on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus target price of $143.70.
Shares of Johnson & Johnson (NYSE JNJ) opened at 141.81 on Wednesday. The company has a 50 day moving average price of $134.68 and a 200-day moving average price of $131.18. The firm has a market cap of $380.62 billion, a PE ratio of 24.66 and a beta of 0.78. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.68%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.68 earnings per share. Analysts expect that Johnson & Johnson will post $7.28 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/27/wells-fargo-company-reaffirms-outperform-rating-for-johnson-johnson-jnj.html.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp lifted its position in shares of Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares during the period. BlackRock Inc. lifted its position in shares of Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares during the period. Janus Henderson Group PLC lifted its position in shares of Johnson & Johnson by 717.9% in the 2nd quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after purchasing an additional 3,289,763 shares during the period. Vanguard Group Inc. lifted its position in shares of Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its position in shares of Johnson & Johnson by 47.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after purchasing an additional 2,581,562 shares during the period. 65.89% of the stock is currently owned by hedge funds and other institutional investors.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.